- Home
- CCIF vs ACRS Comparison
CCIF vs ACRS Comparison
Compare CCIF & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCIF
- ACRS
- Stock Information
- Founded
- CCIF 2011
- ACRS 2012
- Country
- CCIF United States
- ACRS United States
- Employees
- CCIF N/A
- ACRS N/A
- Industry
- CCIF Finance/Investors Services
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- CCIF Finance
- ACRS Health Care
- Exchange
- CCIF Nasdaq
- ACRS Nasdaq
- Market Cap
- CCIF 110.5M
- ACRS 132.0M
- IPO Year
- CCIF N/A
- ACRS 2015
- Fundamental
- Price
- CCIF $7.90
- ACRS $2.57
- Analyst Decision
- CCIF
- ACRS Strong Buy
- Analyst Count
- CCIF 0
- ACRS 5
- Target Price
- CCIF N/A
- ACRS $11.00
- AVG Volume (30 Days)
- CCIF 76.9K
- ACRS 1.0M
- Earning Date
- CCIF 01-01-0001
- ACRS 02-25-2025
- Dividend Yield
- CCIF 25.90%
- ACRS N/A
- EPS Growth
- CCIF N/A
- ACRS N/A
- EPS
- CCIF N/A
- ACRS N/A
- Revenue
- CCIF N/A
- ACRS $27,079,000.00
- Revenue This Year
- CCIF N/A
- ACRS N/A
- Revenue Next Year
- CCIF N/A
- ACRS N/A
- P/E Ratio
- CCIF N/A
- ACRS N/A
- Revenue Growth
- CCIF N/A
- ACRS 26.35
- 52 Week Low
- CCIF $7.43
- ACRS $0.95
- 52 Week High
- CCIF $10.16
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- CCIF 45.64
- ACRS 43.12
- Support Level
- CCIF $7.62
- ACRS $2.31
- Resistance Level
- CCIF $8.06
- ACRS $2.57
- Average True Range (ATR)
- CCIF 0.13
- ACRS 0.18
- MACD
- CCIF -0.00
- ACRS 0.00
- Stochastic Oscillator
- CCIF 64.63
- ACRS 39.45
About CCIF Carlyle Credit Income Fund Shares of Beneficial Interest
Carlyle Credit Income Fund is a non-diversified, closed-end management investment company. The Fund's primary investment objective is to generate current income, with a secondary objective to generate capital appreciation. The Fund seeks to achieve its investment objective by investing primarily in equity and junior debt tranches of collateralized loan obligations, that are collateralized by a portfolio consisting primarily of below-investment-grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.